Corpus ID: 196507359

Synthesis and Evaluation of New HCV NS3/4A Protease Inhibitors

@inproceedings{Koumbaros2013SynthesisAE,
  title={Synthesis and Evaluation of New HCV NS3/4A Protease Inhibitors},
  author={Evangelos Konstantinos Koumbaros},
  year={2013}
}
The Hepatitis C virus infects an estimated 170 million people worldwide, and is the major cause of hepatitis, cirrhosis and liver cancer. The available treatment is a combination therapy with two non-specific antiviral agents, pegylated interferon (Peg-IFN) and ribavirin (RBV), which is effective for only half of the treated patients and has severe side effects. Recent addition of HCV NS3/4A protease inhibitors, Telaprevir and Boceprevir, to the therapy has improved HCV treatment outcomes… Expand

References

SHOWING 1-10 OF 11 REFERENCES
An overview of emerging therapies for the treatment of chronic hepatitis C.
Update on viral hepatitis: 2007
Progress in the development of preventive and therapeutic vaccines for hepatitis C virus.
Epidemiology of hepatitis C virus infection.
Hepatitis C: diagnosis and treatment.
Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation.
  • N. Kato
  • Biology, Medicine
  • Microbial & comparative genomics
  • 2000
Telaprevir for previously treated chronic HCV infection.
Hidden hazards of HCV transmission
...
1
2
...